3 May 2024 - Xpovio (selinexor), the first drug launched in Korea by Antengene, has won recognition to receive reimbursement for treating multiple myeloma from the Pharmaceutical Reimbursement Evaluation Committee, surmounting 80% of barriers to getting insurance benefits.

Sanofi's Dupixent (dupilumab) was also recognised as appropriate for expanded coverage for treating severe paediatric atopic dermatitis, while Latuda (lurasidone), an anti-psychotic drug introduced by Bukwang Pharmaceutical, and Erbitux (cetuximab), an anti-cancer drug developed by Merck, passed the Pharmaceutical Reimbursement Evaluation Committee on the condition that they accept drug prices below the Government's proposed valuation.

Read Korea Biomedical Review article